Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

Publish with us

David Welch


David Welch

Session 1: Biotechnology: Opportunities for formulation and food structuring

Synthesis Capital & The Good Food Institute, USA

David is Chief Scientific Officer and Co-Founder at Synthesis Capital, an investment manager created to transform our food system through food technology. At Synthesis, David combines his background in plant biology, cell therapy, and alternative protein technology to identify exceptional start-ups working at the intersection of food technology, biology, and chemistry and support Synthesis portfolio companies with their technical and scale-up challenges. Prior to joining Synthesis Capital, David was Director of Science and Technology at GFI where he helped start-ups, investors, corporations, and universities accelerate the development, scale-up, and commercialization of alternative protein technology. David previously served in commercial and technical roles within the life science industry at Thermo Fisher Scientific, Qiagen, Meso Scale Discovery, and 3M Healthcare, which included the product development and commercialization of cell reprogramming technologies, scaffolds, cell culture media, and immunoassays for cell therapy and pharmaceutical applications. David earned a B.Sc. in biology from the University of California at Berkeley and a Ph.D. in plant developmental cell biology from Utrecht University.